(Q37074139)

18 August 2017

1 reference

title

Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors (English)

1 reference

18 August 2017

1 reference

1

Margaret A Knowles

0 references

language of work or name

English

0 references

publication date

1 February 2008

1 reference

18 August 2017

1 reference

18 August 2017

4

1 reference

18 August 2017

71-83

1 reference

18 August 2017

1

1 reference

18 August 2017

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

The economic consequences of prostate and bladder cancer in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

High frequency of FGFR3 mutations in adenoid seborrheic keratoses.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Somatic mutation of PTEN in bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Molecular prognostic factors in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Analysis of the performance of pathologists in the grading of bladder tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Urinary basic fibroblast growth factor in bladder cancer patients. Histopathological correlation and clinical potential

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.71

21 January 2018

Identifiers

DOI

10.2217/14796694.4.1.71

1 reference

18 August 2017

1 reference

PubMed ID

18241002